A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer
Clinical trial NCT01358877 · COMPLETED
Trial details
- NCT number
- NCT01358877
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2011-11-08
- Primary completion
- 2016-12-19
- Enrollment
- 4804
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.